Tomahawk, WI 03/14/2014 (Basicsmedia) – DepoMed Inc (NASDAQ:DEPO) shares kept moving upward the second day after it announced its Q4, 2013 results later in the evening of March 12 2014. The stock price gained another 10.67% before closing the day at $14.94.

Financial highlights for Q4 FY 2013

The highlight of the quarterly results was its $40.6 million worth of revenues, which beat analysts’ estimates by more than a 100%. Analysts forecasted revenue of merely $19.06 million. Earnings per share were also 27% up from consensus estimates. The earnings per share reported for last years’ comparable quarter were in negative (i.e. a loss per share of $0.07).

Analysts’ forecasted a loss per share of $0.2 for the current year’s Q4. For the full year 2014 analysts expects the company to break even or get earnings per share of $0.16 (both estimates on non GAAP basis). Thomson Reuters consensus estimate for EPS is $0.29 while another conservative consensus forecast is $0.08.

Product Portfolio Of DepMed

DepoMed Inc (NASDAQ:DEPO) is a specialty pharmaceutical that delivers generic (non-biotech) pain relievers, drugs for neurological diseases, and disorders of CNS. It is actively commercializing several easy to administer (once daily oral intake) treatments for common diseases, like Type II diabetes and more rare ones like Neuralgia.

Mixed sentiments emerged from the response of top Notch investment analysts and credit rating firms to the company’s recent advances.

Analyst’s Ratings and Recommendations

Following the announcement of the quarterly results many analyst’s firm commented on the stock. JPMorgan Chase & Co (NYSE:JPM) Securities which raised their price target in December (about the beginning of the Q4) to $11, have rated the stock as an “outperform”. On the very contrary, employee-owned, RothCapital Partners, LLC, which focuses on a narrower range of investments opportunities (i.e. small cap stocks) did not reverse their recent decision to downgrade the stock to a “Neutral”. Roth’s neutral rating persists since Feburary 13, 2014. They did raise their price target for DepoMed Inc (NASDAQ:DEPO) by $0.5 to $12.5, after the announcement of its quarterly results.

DISCLAIMER: This content is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.